Adia Nutrition Inc. Advances Toward United Healthcare Provider Approval for Adia Med Services, Signaling Major Growth Opportunity
Adia Nutrition Inc. (OTCQB: ADIA) is approaching a significant milestone as its medical subsidiary, Adia Med, nears final approval to become an in-network provider with United Healthcare.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adia Nutrition Inc. (OTCQB: ADIA) is approaching a significant milestone as its medical subsidiary, Adia Med, nears final approval to become an in-network provider with United Healthcare. The anticipated approval, expected by August 1, 2025, will enable insurance coverage for Adia Med's advanced regenerative therapies including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Therapeutic Plasma Exchange (TPE).
The company has already initiated its first patient insurance claim through United Healthcare, signaling progress toward integration. This strategic development will expand Adia Med's market reach by making its treatments accessible to United Healthcare's extensive patient network while establishing a scalable reimbursement pathway in the regenerative medicine sector.
Positive
- None.
Negative
- Final approval still pending
- Currently limited to United Healthcare network only
Details
News Market Reaction – ADIA
The recorded move for ADIA in the trading session of this news was -18.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - July 2, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in advanced regenerative therapies, is pleased to announce that its medical subsidiary, Adia Med, is in the final stages of approval to become an in-network provider with United Healthcare, one of the largest and most influential health insurance companies in the U.S. The company anticipates final approval by August 1, 2025, which will significantly expand Adia Med's market reach by making its cutting-edge medical services eligible for reimbursement under United Healthcare policies.
United Healthcare
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/256142_adianutritionimage.jpg
This strategic milestone positions Adia Nutrition to tap into a vastly larger patient population while driving new revenue streams from insurance-backed procedures such as Autologous Hematopoietic Stem Cell Transplantation (AHSCT), Therapeutic Plasma Exchange (TPE), and stem cell therapies that may be covered under the patient's insurance.
"This anticipated provider agreement with United Healthcare is a pivotal step forward in our growth trajectory," said Larry Powalisz, CEO of Adia Nutrition Inc. "It enables Adia Med to deliver its advanced, high-demand therapies to a broader population with insurance support, opening the door for accelerated patient acquisition and scalable expansion."
Once approved, Adia Med will join a select network of providers meeting United Healthcare's rigorous standards for clinical excellence, compliance, and patient care. The company has already begun submitting its first patient's insurance claim through UnitedHealthcare-a strong signal of imminent integration.
United Healthcare's partnership not only validates the clinical quality of Adia Med's offerings but also provides a scalable reimbursement pathway for advanced treatments in the fast-growing regenerative medicine sector.
For investor inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events, or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256142
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.